Universal NK cells for children with relapsed B-ALL
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an off-the-shelf natural killer (NK) cell treatment for children whose B-cell acute lymphoblastic leukemia (B-ALL) has come back or hasn't responded to standard therapy. The NK cells are designed to target and kill leukemia cells without needing to be a match for your child.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is between 3 and 18 years old
- Their leukemia cells have a marker called CD19 on them
- Their leukemia has come back after treatment or hasn't responded well to chemotherapy
- They are not too sick from other conditions, with reasonable blood counts and organ function
- They don't have active serious infections, other cancers, or a history of severe allergies to biologics
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests donated “natural killer (NK) cells,” a type of immune cell, in children and young adults with AML that has come back or did not respond to treatment. It mainly looks at safety and also studies whether the treatment can help control the leukemia.
This trial tests a new type of immunotherapy using natural killer cells (immune cells that fight cancer) given after a stem cell transplant in children with leukemia or neuroblastoma. The goal is to see if these cells help prevent cancer from coming back and are safe for young patients.
This trial tests a new treatment using special NK cells (a type of immune cell) designed to target and calm overactive B cells that cause autoimmune diseases like lupus and kidney inflammation. It may help children whose current treatments aren't working well enough.
This trial tests a new type of immune cell therapy (called CNK-UT) for children whose neuroblastoma has come back or hasn't responded to standard treatments. The goal is to see if these cells can find and attack the cancer. Participation may be an option if your child's tumor has a specific marker (B7-H3) and their overall health is stable enough.
This trial tests a new natural killer (NK) cell therapy for adults with acute myeloid leukemia (AML) that has returned or not responded to treatment. The therapy targets two specific markers (CLL1 or CD33) on leukemia cells. It aims to see if these immune cells can safely fight the cancer.
This early-stage trial tests a personalized immune-cell treatment called CNCT19 in children and teens whose leukemia (ALL) has come back or not responded to prior therapy. It may help the immune system recognize and attack leukemia cells that carry CD19.
Hear when a new Relapsed/Refractory Pediatric B-ALL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.